-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Metformin is the "star" drug for the treatment of diabetes ; but the "ambition" of metformin does not stop there.
Metformin diabetes
In addition to the role of classic hypoglycemic drugs, the potential health effects of metformin in other disease fields have always been concerned.
At present, a large number of studies have confirmed that metformin can effectively prevent and treat lung cancer, breast cancer , kidney cancer and other malignant tumor diseases, so it has been dubbed the title of "anti-cancer guardian" by scientists.
Two meta-analyses have determined that T2DM will increase the overall risk of BC by 20%, and in turn, BC will increase the risk of T2DM by 27%.
Metformin is usually used as the first-line treatment of T2DM, which can reduce the level of insulin in the circulation, leading to a decrease in signal transmission through the PI3K and ras pathways, or directly through the action on the complex I in the mitochondria, leading to the activation of AMPK mediated by LKB1 And downstream mTOR inhibition to reduce the risk of BC.
Metformin may also affect rag GTPases, cancer stem cells and tumor microenvironment, and may have the greatest anti-cancer effect on triple negative BC (TNBC).
diagnosis
After a median follow-up of 8.
However, compared with patients without T2DM, women with T2DM taking metformin had a 14% lower risk of estrogen receptor (ER)-positive breast cancer (HR=0.
However, compared with patients without T2DM, women with T2DM taking metformin had a 14% lower risk of estrogen receptor (ER)-positive breast cancer (HR=0.
Possible mechanism of metformin lowering BC
Possible mechanism of metformin lowering BCIt is worth mentioning that ER-positive BC is the most common type of breast cancer.
T2DM increases the risk of ER-positive BC by 22% (HR 1.
In summary, the study shows that taking metformin in women with type 2 diabetes can help reduce the risk of ER-positive breast cancer.
In summary, the study shows that taking metformin in women with type 2 diabetes can help reduce the risk of ER-positive breast cancer.
references:
Lohmann AE, Goodwin PJ.
Diabetes, metformin and breast cancer: a tangled web.
Leave a message here
